Epidermolysis Bullosa News and Research

RSS

Tβ4 offers both neurorestoration and neuroprotection after TBI

RegeneRx Biopharmaceuticals, Inc. reported that data showing that Thymosin beta 4 (Tβ4) "provides both neuroprotection and neurorestoration after traumatic brain injury (TBI)," was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081-1092.

28 May 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

RegeneRx's RGN-259 safe, well tolerated in patients with dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating RGN-259 for the treatment of dry eye syndrome.

5 Jan 2012

Towards a national plan of action for rare diseases

"Rare diseases", by their very definition, occur in no more than 5 people out of every 10,000 inhabitants. Barely noticed by the general public, only around 1,000 of the currently 6,000 or so different rare diseases currently listed on the Internet platform Orphanet are treatable nowadays.

5 Dec 2011

Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

18 Nov 2011

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that the first patients have been enrolled and randomized to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

16 Aug 2011

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome.

29 Jul 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011

Thymosin beta 4 can transform adult epicardial stem cells into functional heart muscle

RegeneRx Biopharmaceuticals, Inc. has announced that thymosin beta 4 (Tβ4) can activate a unique subpopulation of resident adult epicardial stem cells such that they recapture embryonic potential, proliferate, migrate and differentiate into functional heart muscle (cardiomyocytes), according to a research paper published online today in Nature.

9 Jun 2011

Tβ4 activates Akt survival kinase and reduces heart attack damage

RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.

7 Jun 2011

RegeneRx Thymosin beta 4 stimulates maturation of central nervous system progenitor cells

RegeneRx Biopharmaceuticals, Inc. has announced that researchers have found that Thymosin beta 4 (Tβ4), in a dose dependent manner, stimulates oligodendrogenesis, the process by which central nervous system progenitor cells become oligodendrocytes that secrete myelin, the covering of nerve fibers.

2 Jun 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA's current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the Company's Phase 2 clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

16 Mar 2011

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.

23 Feb 2011

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been included on MDB Capital Group's "Best & Brightest" innovators list of 150 companies for 2011. Criterion for inclusion is a ranking in the 90th percentile for technology leadership from more than 1,500 companies with U.S. patents granted, as rated by PatentVest®, MDB's proprietary, intellectual property (IP), business intelligence database.

19 Feb 2011

Study: Tβ4 can protect endothelial progenitor cells

RegeneRx Biopharmaceuticals, reported that a team of cardiovascular researchers in China have shown that Tβ4 can protect endothelial progenitor cells derived from the blood of healthy human volunteers.

7 Jan 2011

RegeneRx common stock to be quoted on OTC Bulletin Board following NYSE Amex suspension

RegeneRx Biopharmaceuticals, Inc. announced today that beginning with the opening of trading on December 23, 2010, the Company's common stock is expected to be quoted on the OTC Bulletin Board under the symbol RGRX following its suspension from the NYSE Amex as of that date.

24 Dec 2010

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010